Biogen Inc. (FRA:IDP)
Germany
· Delayed Price · Currency is EUR 111.80
-0.95 (-0.84%)
Last updated: Jul 4, 2025
Biogen Revenue
Biogen had revenue of $2.43B USD in the quarter ending March 31, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $9.82B, up 1.59% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.82B
Revenue Growth
+1.59%
P/S Ratio
1.82
Revenue / Employee
$1.29M
Employees
7,605
Market Cap
16.55B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 109.03B |
| Rheinmetall AG | 10.48B |
| Siemens Energy AG | 37.44B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Healthineers AG | 23.14B |
Biogen News
- 4 days ago - Biogen starts phase 3 trial of felzartamab for kidney disease - Seeking Alpha
- 4 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 7 days ago - Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy - Seeking Alpha
- 7 days ago - New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA - GlobeNewsWire
- 9 days ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 9 days ago - Biogen’s salanersen shows promise in SMA, heads toward registrational trials - Seeking Alpha
- 9 days ago - Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results - Wallstreet:Online
- 9 days ago - Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? - Investor's Business Daily